Childhood Cancer Clinical Trials Act
A BILL
To amend title XXVII of the Public Health Service Act to require out-of-network coverage for qualified individuals diagnosed with a rare pediatric disease participating in approved clinical trials, and for other purposes.
Sec. 2 Amendments relating to coverage in individual and group market and under Medicare program for qualified individuals diagnosed with a rare pediatric disease participating in approved clinical trials
“(c) Treatment of non-Participating providers
“(1) In general—Subject to paragraph (2), this section shall not be construed to require a group health plan, or a health insurance issuer offering group or individual health insurance coverage, to provide benefits for routine patient care services provided outside of the plan's (or coverage's) health care provider network unless out-of-network benefits are otherwise provided under the plan (or coverage).
“(2) Qualified individuals diagnosed with a rare pediatric disease—In the case of a qualified individual diagnosed with a rare pediatric disease, with respect to routine patient costs for items and services furnished to such individual in connection with participation in an approved clinical trial by a nonparticipating provider, a group health plan or health insurance issuer offering group or individual health insurance coverage that provides coverage to such individual—
“(A) shall impose the same cost-sharing requirement (expressed as a copayment amount or coinsurance rate) that would apply if such item or service was furnished by a participating provider; and
“(B) shall pay to such nonparticipating provider the amount by which the recognized amount for such item or service exceeds the cost-sharing amount for such item or service (as determined in accordance with subparagraph (A)).”
“(i) Other definitions
“(1) Nonparticipating provider; participating provider; recognized amount—For purposes of this section, the terms “nonparticipating provider”, “participating provider”, and “recognized amount” have the meaning given such terms in section 2799A–1(a)(3).
“(2) Rare pediatric disease—The term “rare pediatric disease” has the meaning given such term in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act.”
“(i) all items and services”
“(ii) consultation and referral services relating to approved clinical trials furnished to qualified individuals.”
“(viii) The Patient-Centered Outcomes Research Institute.”
“(3) Routine costs of care—In defining “routine costs of care” for purposes of paragraph (1), the Secretary shall define such term in a manner that provides for coverage of consultation and referral services furnished to an individual in the course of participation in a category A clinical trial.”